| Website | agtc.com |
| Category | BioTech |
| Phone | 3864622204 |
| webmaster@agtc.com | |
| Employees | |
| Founded | 1/09 |
| Description | Gene therapy |
| TOTAL | $77.3M |
| FUNDING TOTAL | $77.3M |
| Series B, 11/03 InterWest Partners Skyline Ventures InterSouth Partners MedImmune Ventures | $27M |
| Series C, 6/09 InterSouth Partners InterWest Partners MedImmune Ventures | $11.8M |
| Grant, 9/10 | $1M |
| Series B, 11/12 Alta Partners Osage University Partners InterWest Partners InterSouth Partners MedImmune Ventures SR One | $37.5M |
Applied Genetic Technologies Corporation (AGTC) was founded by five scientific leaders in the use of viral vectors for Gene Therapy and began operations in 2001. They subsequently secured rights to a portfolio of strategically vital intellectual property in the application of Adeno-Associated Virus (AAV) to gene therapy. Since that time the Company has signed licenses to over 40 US and foreign patents, raised over $45M in venture financing from blue chip investors and has five products in active development, one of which is partnered to Genzyme Corporation.
AGTC’s most recent round of financing was completed in April 2009 and was led by Interwest Partners of Menlo Park, CA. Other investors included Intersouth Partners of RTP, NC and MedImmune Ventures of Gaithersburg, MD.
